From the perspective of ranking, there are not many multinational pharmaceutical companies maintaining the growth momentum. Among the top 20 pharmaceutical companies, 13 saw a decline in market value, with Bayer's decline as high as 28.5%; followed by GlaxoSmithKline (16.7%), Amgen (16.5%), Pfizer (16.5%), Bristol Myers Squibb (16.2%) and MSD (15.7%).

 

 

 

The top three rankings have also changed, with Pfizer's new ranking dropping from "big brother" to fifth, plummeting. Johnson, Roche and Novartis became the top three.

 

 

 

Johnson & Johnson's market value fell 10% in the first quarter, but the company remained a leader in the rankings. Johnson & Johnson is also facing many challenges, such as REMICADE and zytiga, which have been impacted by generic drugs.

 

 

 

Roche's market value rose 3.6% in the first quarter of this year, which is related to its anti-inflammatory drug actemra. According to Roche's recent financial report, actemra's sales increased by 30% in the first quarter to CHF 666 million. In addition, Roche's contribution to the field of cancer is indispensable. With the continuous growth of tumor drugs, Roche relies on the advantage of tumor pipeline to occupy the first position of tumor.

 

 

 

Novartis is still in the top three. The industry believes that this is closely related to its emphasis on R & D, especially the strong development of Novartis in China and its tumor advantages. At present, Novartis focuses on five key cancer areas: breast cancer, lung cancer, melanoma, renal cancer and hematology.

 

 

 

It is understood that since 2017, Novartis tumor (China) is introducing a number of innovative drugs targeted at treatment into the Chinese market at the rate of 1-3 new products or new indications every year. Currently, the innovative drugs introduced include Czech Wei for the treatment of bone marrow fibrosis, weiquante for the treatment of advanced renal cancer, Revan for the treatment of primary immune thrombocytopenia and Zanda for the treatment of non-small cell lung cancer Wait.

 

 

 

In addition, the obvious change is that Bayer, GSK and Sanofi have quit the top ten clubs, of which Bayer has dropped to the 18th place in the world.

 

 

 

It is worth mentioning that in the first quarter of this year, the only pharmaceutical companies with market value growth of more than 10% were Zaiyuan and Geely tech. Among them, the growth of regenerator reached 32.5%, mainly due to the contribution of kevzara, an anti-inflammatory drug, which had been tested in two key clinical trials by the end of March. Currently, the company is preparing antibody mixtures for clinical trials in the summer.

 

 

 

Gilead's market capitalisation increased by 14.5%, mainly due to its remdesivir. In early April, Gilead said it had stepped up its production schedule for the drug and increased its production so as to produce 1 million Ridgeway units by the end of this year. However, according to the draft report, the three phase randomized controlled clinical trials of ridcivir in China failed. Affected by the news, Gilead's share price fell by more than 8%. In May, Gilead will release clinical data in the United States and Europe, which the industry believes may have a more direct impact on Gilead's market value in the second quarter of this year.

 

 

 

In general, the first quarter of this year is full of challenges for large pharmaceutical companies. The industry believes that the cumulative decline of market value of 7.9% is not as bad as it seems, but undoubtedly, the competition among multinational pharmaceutical companies will become more fierce in the future.